Malignant fibrous histiocytoma: Database review suggests a favorable prognosis in the head and neck

• Published in: The Laryngoscope 2018-04, Vol.128 (4), p.885-888
• Main Authors: Borucki, Robert B., Neskey, David M., Lentsch, Eric J.
• Format: Article
• Language: English
• Subjects: head and neck; Malignant fibrous histiocytoma; Medical prognosis; Sarcoma; SEER; survival; Tumors
• ISSN: 0023-852X; 1531-4995
• DOI: 10.1002/lary.26909

Objective The malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma of the head and neck. Currently, most of the data on this tumor relies on small retrospective studies. The objective of this study is to use the Surveillance, Epidemiology, and End Results (SEER) database to compare characteristics of this tumor based on location to better understand its prognosis in the head and neck region. This article represents the largest study analyzing prognosis of this tumor in the head and neck to date. Study Design Retrospective analysis of SEER database. Methods Using the SEER database, 395 patients with MFH of the head and neck were compared with 3,968 patients with MFH of the trunk and extremities. Disease‐specific survival was carried out comparing these two cohorts, as well as univariate and multivariate analysis to determine hazard ratios. Results Head and neck MFH had a significantly higher disease‐specific survival compared with trunk and extremity disease. However, head and neck tumors were more frequently a smaller size (P < .0001) and lower grade (P < .0001). Larger tumors and grade III and IV tumors conferred a worse prognosis (P < .0001). Conclusion Head and neck malignant fibrous histiocytoma presents at a smaller size and lower grade, likely due to earlier presentation in this region. Because of this, head and neck malignant fibrous histiocytoma represents a more favorable survival prognosis compared with trunk and extremity disease. Level of Evidence 4. Laryngoscope, 128:885–888, 2018